Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.

Anuradha Jayaram,Karolina Nowakowska,Joaquin Mateo,Sanjeev Kumar,Tatiana Hernandez,B. Fulton,Daniel Nava Rodrigues,Ruth Riisnaes,Alexander Zukiwski,Alice Susannah Bexon,Stefan Proniuk,Charles Barranco,Diletta Bianchini,Zafeiris Zafeirou,Raquel Perez Lopez,Nina Tunariu,Simon Pacey,Robert Jones,Johann S. de Bono,Gerhardt Attard

Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.

2017

5071Background: An urgent need exists for new therapies after progression (PD) onAA and enzalutamide (ENZ). Increased PR expression or progesterone-activating AR mutations have been associated with...

Keywords:

ER Onapristone
Abiraterone
Androgen receptor
DNA
Pathology
Prostate cancer
Cancer research
Castration
Medicine
Progesterone receptor
Enzalutamide
in patient
extended release
plasma dna

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations